Treos Bio, Inc. develops precision cancer immunotherapies tailored to patients' genetics.
Treos Bio has raised $2.1M in total funding. The most recent round was Convertible Note. The last funding was announced in August 2025.
Treos Bio's investors include The Future Fund, Luminous Ventures, BXR Partners LLP.
Treos Bio is headquartered in London, United Kingdom.
Treos Bio, Inc. develops precision cancer immunotherapies tailored to patients' genetics.
Treos Bio is at the Convertible Note stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Treos Bio — Funding & Investors." VCBacked, August 27, 2025, https://www.vcbacked.co/company/treos-bio. Accessed September 30, 2026.
VCBacked. (2025). Treos Bio — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/treos-bio
{{cite web |title=Treos Bio — Funding & Investors |url=https://www.vcbacked.co/company/treos-bio |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated